Citations (103)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Shogo Matsumoto, Shotaro Uehara, Hidetaka Kamimura, Naoki Cho, Hiroshi Ikeda, Satoshi Maeda, Kensuke Kagiyama, Atsunori Miyata, Hiroshi Suemizu & Kazumasa Fukasawa. (2022) Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets. Xenobiotica 52:6, pages 613-624.
Read now
Read now
Mohammad Abumayyaleh, Ibrahim El-Battrawy, Michael Behnes, Martin Borggrefe & Ibrahim Akin. (2020) Current Evidence of sacubitril/valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction. Future Cardiology 16:4, pages 227-236.
Read now
Read now
Marwa H. Tammam & Nisreen F. Abo-Talib. (2019) Development and Validation of a Bioanalytical HPLC Method for Quantification of Valsartan in Human Plasma and its Application in Pharmacokinetics Studies. Analytical Chemistry Letters 9:5, pages 672-681.
Read now
Read now
Imad Hanna, Natalya Alexander, Matthew H. Crouthamel, John Davis, Adrienne Natrillo, Phi Tran, Arpine Vapurcuyan & Bing Zhu. (2018) Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition. Xenobiotica 48:3, pages 300-313.
Read now
Read now
Jimmy Flarakos, Yancy Du, Timothy Bedman, Qusai Al-Share, Pierre Jordaan, Priya Chandra, Diego Albrecht, Lai Wang, Helen Gu, Heidi J. Einolf, Su-Er Huskey & James B. Mangold. (2016) Disposition and metabolism of [14C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects. Xenobiotica 46:11, pages 986-1000.
Read now
Read now
Hakan Serbest, Sezgin Bakırdere & Seyfullah Keyf. (2016) Development of an analytical method for the determination of valsartan in commercial drug and sewage sludge samples by HPLC and evaluation of its stability under simulated gastric conditions. Journal of Liquid Chromatography & Related Technologies 39:11, pages 526-531.
Read now
Read now
Jin Ah Jung, Soo-Yun Lee, Jung-Ryul Kim, Jae-Wook Ko, Seong Bok Jang, Su Youn Nam & Wooseong Huh. (2015) A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects. Drug Design, Development and Therapy 9, pages 745-752.
Read now
Read now
Vijaykumar Nekkanti, Natarajan Venkatesan, Zhijun Wang & Guru V. Betageri. (2015) Improved oral bioavailability of valsartan using proliposomes: design, characterization and in vivo pharmacokinetics. Drug Development and Industrial Pharmacy 41:12, pages 2077-2088.
Read now
Read now
Fotini Gialama & Nikos Maniadakis. (2013) Comprehensive overview: efficacy, tolerability, and cost-effectiveness of irbesartan. Vascular Health and Risk Management 9, pages 575-592.
Read now
Read now
Adriaan A Voors, Bernard Dorhout & Peter van der Meer. (2013) The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opinion on Investigational Drugs 22:8, pages 1041-1047.
Read now
Read now
Cassandra D Benge & James A S Muldowney$suffix/text()$suffix/text(). (2012) The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1469-1482.
Read now
Read now
Manu Kaushik & Syed M Mohiuddin. (2011) Clinical utility of valsartan in treatment of children and adolescents with high blood pressure. Adolescent Health, Medicine and Therapeutics 2, pages 97-103.
Read now
Read now
Artavazd Tadevosyan, Eric J MacLaughlin & Vardan T Karamyan. (2011) Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. Patient Related Outcome Measures 2, pages 27-39.
Read now
Read now
Jujhar Bains & William B Smith. (2011) Valsartan plus hydrochlorothiazide: a review of its use since its introduction. Expert Opinion on Pharmacotherapy 12:12, pages 1975-1984.
Read now
Read now
Nisha B Mistry, Arne S Westheim & Sverre E Kjeldsen. (2006) The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opinion on Pharmacotherapy 7:5, pages 575-581.
Read now
Read now
Sverre E Kjeldsen, Hans R Brunner, Gordon T McInnes & Pelle Stolt. (2005) Valsartan in The Treatment of Hypertension. Aging Health 1:1, pages 27-36.
Read now
Read now
Steffen Böhler, David Pittrow, Peter Bramlage & Wilhelm Kirch. (2005) Drug interactions with angiotensin receptor blockers. Expert Opinion on Drug Safety 4:1, pages 7-18.
Read now
Read now
Petra A Thürmann. (2000) Valsartan: a novel angiotensin Type 1 receptor antagonist. Expert Opinion on Pharmacotherapy 1:2, pages 337-350.
Read now
Read now
Arnaud Chiolro & Michel Burnier. (1998) Pharmacology of valsartan, an angiotensin II receptor antagonist. Expert Opinion on Investigational Drugs 7:11, pages 1915-1925.
Read now
Read now
Articles from other publishers (83)
Antonio Medici, Margherita Lavorgna, Marina Isidori, Chiara Russo, Elena Orlo, Giovanni Luongo, Giovanni Di Fabio & Armando Zarrelli. (2024) Advanced oxidation process of valsartan by activated peroxymonosulfate: Chemical characterization and ecotoxicological effects of its byproducts. Science of The Total Environment 908, pages 168337.
Crossref
Crossref
Ryota Kikuchi, Paresh P. Chothe, Xiaoyan Chu, Felix Huth, Kazuya Ishida, Naoki Ishiguro, Rongrong Jiang, Hong Shen, Simone H. Stahl, Manthena V.S. Varma, Marie‐Emilie Willemin & Bridget L. Morse. (2023) Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry. Clinical Pharmacology & Therapeutics 114:6, pages 1170-1183.
Crossref
Crossref
Valentin Göldner, Jessica Ulke, Benedict Kirchner, Dominik Skalka, Marie Schmalz, Steffen Heuckeroth & Uwe Karst. (2023) Electrochemistry-mass spectrometry bridging the gap between suspect and target screening of valsartan transformation products in wastewater treatment plant effluent. Water Research 244, pages 120525.
Crossref
Crossref
Bo Qiu, Haojing Song, Congyang Ding, Xue Sun, Runxuan Du, Haotian Yang, Wanjun Bai & Zhanjun Dong. (2023) Pharmacokinetics and safety of highly variable valsartan in single-pill combination with amlodipine versus its generic formulation: a randomized, three-cycle, three-sequence, partially replicated crossover phase I bioequivalence clinical trial. Frontiers in Pharmacology 14.
Crossref
Crossref
Xue-Ting Shao, Yue-Tong Zhao, Bing Jiang, Yan-Ying Li, Jian-Guo Lin & De-Gao Wang. (2023) Evaluation of Three Chronic Diseases by Selected Biomarkers in Wastewater. ACS ES&T Water 3:4, pages 943-953.
Crossref
Crossref
Susanne Glowienke, Ulrich Onken, Azeddine Elhajouji, Sasikumar Muthusamy, Ramachandra Sangana, Hans-Joerg Martus, Timothy Bedman & Andreas Hartmann. (2022) Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity. Regulatory Toxicology and Pharmacology 134, pages 105245.
Crossref
Crossref
Gonjin Song, Jee-Eun Chung, Jeong Yee, Kyung-Eun Lee, Kyungsoo Park & Hye-Sun Gwak. (2021) Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers. Journal of Personalized Medicine 11:9, pages 862.
Crossref
Crossref
Mehrnoush Taherzadeh Ghahfarrokhi, Shakiba Zeinali & Habib Bagheri. (2021) Preparation of amine–modified lignin and its applicability toward online micro–solid phase extraction of valsartan and losartan in urine samples. Journal of Chromatography A 1643, pages 462081.
Crossref
Crossref
Kenichi Umehara, Carina Cantrill, Matthias Beat Wittwer, Elisa Di Lenarda, Florian Klammers, Aynur Ekiciler, Neil Parrott, Stephen Fowler & Mohammed Ullah. (2020) Application of the Extended Clearance Classification System (ECCS) in Drug Discovery and Development: Selection of Appropriate In Vitro Tools and Clearance Prediction. Drug Metabolism and Disposition 48:10, pages 849-860.
Crossref
Crossref
Liang Jin, Yijun Pan, Natalie Lan Linh Tran, Leon N. Polychronopoulos, Aparna Warrier, Kim L. R. Brouwer & Joseph A. Nicolazzo. (2020) Intestinal Permeability and Oral Absorption of Selected Drugs Are Reduced in a Mouse Model of Familial Alzheimer’s Disease. Molecular Pharmaceutics 17:5, pages 1527-1537.
Crossref
Crossref
Seokuee Kim, Jae‐Wook Ko & Jung‐Ryul Kim. (2019) Pharmacokinetic and Safety Profiles of a Fixed‐Dose Combination of Amlodipine, Valsartan, and Atorvastatin: A 3‐Period Replicate Crossover Study. Clinical Pharmacology in Drug Development 9:3, pages 386-394.
Crossref
Crossref
Marwa A. A. Ragab, Mohamed A. Korany, Shereen M. Galal & Aya R. Ahmed. (2019) Voltammetric study of valsartan–Ni complex: application to valsartan analysis in pharmaceuticals and in vivo human urine profiling. Chemical Papers 73:5, pages 1209-1219.
Crossref
Crossref
Dawn Battise, Cassie L. Boland & Donald S. Nuzum. (2018) Nebivolol/Valsartan: A Novel Antihypertensive Fixed-Dose Combination Tablet. Annals of Pharmacotherapy 53:4, pages 402-412.
Crossref
Crossref
Nisha Mistry, Sverre E. Kjeldsen & Arne Westheim. 2019. Hypertension and Heart Failure. Hypertension and Heart Failure
245
260
.
Jun-Bom Park, Chulhun Park, Zhong Zhu Piao, Hardik H. Amin, Nilesh M. Meghani, Phuong H.L. Tran, Thao T.D. Tran, Jing-Hao Cui, Qing-Ri Cao, Euichaul Oh & Beom-Jin Lee. (2018) pH-independent controlled release tablets containing nanonizing valsartan solid dispersions for less variable bioavailability in humans. Journal of Drug Delivery Science and Technology 46, pages 365-377.
Crossref
Crossref
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu & Gangadhar Sunkara. (2017) Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor–Neprilysin Inhibitor. Clinical Pharmacokinetics 57:1, pages 105-123.
Crossref
Crossref
Surya Ayalasomayajula, Thomas Langenickel, Parasar Pal, Sreedevi Boggarapu & Gangadhar Sunkara. (2017) Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics 56:12, pages 1461-1478.
Crossref
Crossref
Surya Ayalasomayajula, Wei Pan, Yi Han, Fan Yang, Thomas Langenickel, Parasar Pal, Wei Zhou, Yaozong Yuan, Iris Rajman & Gangadhar Sunkara. (2016) Assessment of Drug–Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects. European Journal of Drug Metabolism and Pharmacokinetics 42:2, pages 309-318.
Crossref
Crossref
Ana Sofía Londero, Maite Rocío Arana, Virginia Gabriela Perdomo, Guillermo Nicolás Tocchetti, Felipe Zecchinati, Carolina Inés Ghanem, María Laura Ruiz, Juan Pablo Rigalli, Aldo Domingo Mottino, Fabiana García & Silvina Stella Maris Villanueva. (2017) Intestinal multidrug resistance-associated protein 2 is down-regulated in fructose-fed rats. The Journal of Nutritional Biochemistry 40, pages 178-186.
Crossref
Crossref
Yi Han, Surya Ayalasomayajula, Wei Pan, Fan Yang, Yaozong Yuan, Thomas Langenickel, Markus Hinder, Sampath Kalluri, Parasar Pal & Gangadhar Sunkara. (2016) Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. European Journal of Drug Metabolism and Pharmacokinetics 42:1, pages 109-116.
Crossref
Crossref
Bradley T. Andresen, Shane D. Anderson, Jae Kyung Yeon & Rudolf Mireles. 2017. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Estrellita Uijl, Lodi C. W. Roksnoer, Ewout J. Hoorn & A. H. Jan Danser. (2016) From ARB to ARNI in Cardiovascular Control. Current Hypertension Reports 18:12.
Crossref
Crossref
M.H. Sanad, Kh.M. Sallam, F.A. Marzook & S.M. Abd‐Elhaliem. (2016) Radioiodination and biological evaluation of candesartan as a tracer for cardiovascular disorder detection. Journal of Labelled Compounds and Radiopharmaceuticals 59:12, pages 484-491.
Crossref
Crossref
Surya P. Ayalasomayajula, Thomas H. Langenickel, Pierre Jordaan, Wei Zhou, Priyamvada Chandra, Diego Albrecht, Parasar Pal, Iris Rajman & Gangadhar Sunkara. (2016) Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. European Journal of Clinical Pharmacology 72:9, pages 1065-1073.
Crossref
Crossref
Vijaykumar Nekkanti, Zhijun Wang & Guru V. Betageri. (2015) Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System. AAPS PharmSciTech 17:4, pages 851-862.
Crossref
Crossref
Seung Jun Yang, Bong Jin Kim, Lingxuan Mo & Hyo‐Kyung Han. (2016) Alteration of the intravenous and oral pharmacokinetics of valsartan via the concurrent use of gemfibrozil in rats. Biopharmaceutics & Drug Disposition 37:5, pages 245-251.
Crossref
Crossref
Mir Ali Farajzadeh, Parisa Khorram & Azar Pazhohan. (2016) Simultaneous determination of atorvastatin and valsartan in human plasma by solid-based disperser liquid–liquid microextraction followed by high-performance liquid chromatography–diode array detection. Journal of Chromatography B 1017-1018, pages 62-69.
Crossref
Crossref
Lu Gan, Thomas Langenickel, Jesika Petruck, Kiran Kode, Iris Rajman, Priya Chandra, Wei Zhou, Sam Rebello & Gangadhar Sunkara. (2016) Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. The Journal of Clinical Pharmacology 56:1, pages 78-86.
Crossref
Crossref
Lu Gan, Xuemin Jiang, Anisha Mendonza, Therese Swan, Christine Reynolds, Joanne Nguyen, Parasar Pal, Srikanth Neelakantham, Marion Dahlke, Thomas Langenickel, Iris Rajman, Mizuki Akahori, Wei Zhou, Sam Rebello & Gangadhar Sunkara. (2015) Pharmacokinetic drug–drug interaction assessment of LCZ696 (an angiotensin receptor neprilysin inhibitor) with omeprazole, metformin or levonorgestrel‐ethinyl estradiol in healthy subjects. Clinical Pharmacology in Drug Development 5:1, pages 27-39.
Crossref
Crossref
Hsiu‐ling Hsiao, Thomas Heiko Langenickel, Michael Greeley, John Roberts, Wei Zhou, Parasar Pal, Sam Rebello, Iris Rajman & Gangadhar Sunkara. (2015) Pharmacokinetic drug–drug interaction assessment between LCZ696, an angiotensin receptor neprilysin inhibitor, and hydrochlorothiazide, amlodipine, or carvedilol. Clinical Pharmacology in Drug Development 4:6, pages 407-417.
Crossref
Crossref
S. S. Sheen, R. W. Park, D. Yoon, G.-T. Shin, H. Kim & I.-W. Park. (2015) The Model for End-stage Liver Disease score is potentially a useful predictor of hyperkalemia occurrence among hospitalized angiotensin receptor blocker users. Journal of Clinical Pharmacy and Therapeutics 40:1, pages 48-54.
Crossref
Crossref
Shankar Ganesh Gadepalli, Pragney Deme, Madhusudana Kuncha & Ramakrishna Sistla. (2014) Simultaneous determination of amlodipine, valsartan and hydrochlorothiazide by LC–ESI-MS/MS and its application to pharmacokinetics in rats. Journal of Pharmaceutical Analysis 4:6, pages 399-406.
Crossref
Crossref
Gangadhar Sunkara, Girish Bende, Anisha E. Mendonza, Susan Solar‐Yohay, Shibadas Biswal, Srikanth Neelakantham, Robert Wagner, Jimmy Flarakos, Yiming Zhang & Venkateswar Jarugula. (2013) Bioavailability of valsartan oral dosage forms. Clinical Pharmacology in Drug Development 3:2, pages 132-138.
Crossref
Crossref
M. L. Maksimov, A. S. Ermolaeva & O. V. Dralova. (2013) VALSARTAN IN PHARMACOTHERAPY OF CARDIOVASCULAR DISEASES. "Arterial’naya Gipertenziya" ("Arterial Hypertension") 19:5, pages 458-471.
Crossref
Crossref
Meixia Chen. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
2
.
Mohsen A. Hedaya & Sally A. Helmy. (2013) Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, 4-Period Crossover Study in Healthy Egyptian Male Volunteers. Clinical Therapeutics 35:6, pages 846-861.
Crossref
Crossref
Martin C. Michel, Carolyn Foster, Hans R. Brunner & Lisheng Liu. (2013) A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists. Pharmacological Reviews 65:2, pages 809-848.
Crossref
Crossref
A. M. Amin, A. Abd El-bary, A. Abd El-Mohty, Shokry M. Saad & D. M. El-Sharawy. (2013) Radioiodination and biological evaluation of valsartan as a tracer for cardiovascular disorder detection. Natural Science 05:04, pages 526-531.
Crossref
Crossref
Teresa Cabaleiro, Manuel Román, Dolores Ochoa, María Talegón, Rocío Prieto-Pérez, Aneta Wojnicz, Rosario López-Rodríguez, Jesús Novalbos & Francisco Abad-Santos. (2013)
Evaluation of the Relationship between Sex, Polymorphisms in
CYP2C8
and
CYP2C9
, and Pharmacokinetics of Angiotensin Receptor Blockers
. Drug Metabolism and Disposition 41:1, pages 224-229.
Crossref
Crossref
Makoto Kataoka, Tadayuki Takashima, Tomotaka Shingaki, Yoshinobu Hashidzume, Yumiko Katayama, Yasuhiro Wada, Hiroyuki Oh, Yoshie Masaoka, Shinji Sakuma, Yuichi Sugiyama, Shinji Yamashita & Yasuyoshi Watanabe. (2012) Dynamic Analysis of GI Absorption and Hepatic Distribution Processes of Telmisartan in Rats Using Positron Emission Tomography. Pharmaceutical Research 29:9, pages 2419-2431.
Crossref
Crossref
Alexander V. LyubimovHong Liu & Richard Voorman. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
40
.
Gian Camenisch & Ken‐ichi Umehara. (2012)
Predicting human hepatic clearance from
in vitro
drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug–drug interactions
. Biopharmaceutics & Drug Disposition 33:4, pages 179-194.
Crossref
Crossref
Chun Wu, Yanpeng Hu, Qianbin Li, Limei He, Jun Chen, Zeneng Cheng, Yuanjian Li & Gaoyun Hu. (2012) Synthesis, Pharmacokinetics, and Pharmacodynamics Studies of Valsartan Peptide Derivatives. Archiv der Pharmazie 345:5, pages 393-400.
Crossref
Crossref
Ritesh Sharma & Shyam Pancholi. (2012) Simple RP-HPLC method for determination of triple drug combination of valsartan, amlodipine and hydrochlorothiazide in human plasma. Acta Pharmaceutica 62:1, pages 45-58.
Crossref
Crossref
Kevin E. C. Meyers, Kenneth Lieberman, Susan Solar-Yohay, Guangyang Han & Victor Shi. (2011) The Efficacy and Safety of Valsartan in Obese and Non-Obese Pediatric Hypertensive Patients. The Journal of Clinical Hypertension 13:10, pages 758-766.
Crossref
Crossref
Agnès Poirier, Anne-Christine Cascais, Christoph Funk & Thierry Lavé. (2009) Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data. Journal of Pharmacokinetics and Pharmacodynamics 36:6, pages 585-611.
Crossref
Crossref
Oskar Gonzalez, Gorka Iriarte, Nerea Ferreirós, Miren Itxaso Maguregui, Rosa Maria Alonso & Rosa Maria Jiménez. (2009) Optimization and validation of a SPE-HPLC-PDA-fluorescence method for the simultaneous determination of drugs used in combined cardiovascular therapy in human plasma. Journal of Pharmaceutical and Biomedical Analysis 50:4, pages 630-639.
Crossref
Crossref
Agnès Poirier, Anne‐Christine Cascais, Christoph Funk & Thierry Lavé. (2009)
Prediction of Pharmacokinetic Profile of Valsartan in Humans Based on
in vitro
Uptake‐Transport Data
. Chemistry & Biodiversity 6:11, pages 1975-1987.
Crossref
Crossref
Jeffrey Blumer, Donald L. Batisky, Thomas Wells, Victor Shi, Susan Solar‐Yohay & Gangadhar Sunkara. (2013) Pharmacokinetics of Valsartan in Pediatric and Adolescent Subjects With Hypertension. The Journal of Clinical Pharmacology 49:2, pages 235-241.
Crossref
Crossref
Shakil Aslam. (2009) Fixed-dose Combination Therapy in Hypertension: Focus on Fixed-dose combination of Amlodipine and Valsartan (Exforge®). Clinical Medicine. Therapeutics 1, pages CMT.S1982.
Crossref
Crossref
Bahru Habtemariam, William Sallas, Gangadhar Sunkara, Steven Kern, Venkateswar Jarugula & Goonaseelan Pillai. (2009) Population Pharmacokinetics of Valsartan in Pediatrics. Drug Metabolism and Pharmacokinetics 24:2, pages 145-152.
Crossref
Crossref
Zong-Zhu Piao, Eung-Seok Lee, Huyen Thi Thanh Tran & Beom-Jin Lee. (2008) Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection. Archives of Pharmacal Research 31:8, pages 1055-1059.
Crossref
Crossref
Yan‐Ling He, Monica Ligueros‐Saylan, Gangadhar Sunkara, Ron Sabo, Charlie Zhao, Yibin Wang, Joelle Campestrini, Françoise Pommier, Kiran Dole, Alan Marion, Willia P. Dole & Dan Howard. (2013) Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects. The Journal of Clinical Pharmacology 48:1, pages 85-95.
Crossref
Crossref
Gorka Iriarte, Nerea Ferreirós, Izaskun Ibarrondo, Rosa Maria Alonso, Miren Itxaso Maguregui & Rosa Maria Jiménez. (2007) Biovalidation of an SPE‐HPLC‐UV‐fluorescence method for the determination of Valsartan and its metabolite valeryl‐4‐hydroxy‐valsartan in human plasma. Journal of Separation Science 30:14, pages 2231-2240.
Crossref
Crossref
Nozomu Koseki, Hiroto Kawashita, Hisanori Hara, Miyuki Niina, Makoto Tanaka, Ryosei Kawai, Yusuke Nagae & Naoki Masuda. (2007) Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 43:5, pages 1769-1774.
Crossref
Crossref
Emi Kamiyama, Yasushi Yoshigae, Atsushi Kasuya, Makoto Takei, Atsushi Kurihara & Toshihiko Ikeda. (2007) Inhibitory Effects of Angiotensin Receptor Blockers on CYP2C9 Activity in Human Liver Microsomes. Drug Metabolism and Pharmacokinetics 22:4, pages 267-275.
Crossref
Crossref
Gorka Iriarte, Nerea Ferreirós, Izaskun Ibarrondo, Rosa Maria Alonso, Miren Itxaso Maguregi, Lorena Gonzalez & Rosa Maria Jiménez. (2006)
Optimization
via
experimental design of an SPE‐HPLC‐UV‐fluorescence method for the determination of valsartan and its metabolite in human plasma samples
. Journal of Separation Science 29:15, pages 2265-2283.
Crossref
Crossref
Wakaba Yamashiro, Kazuya Maeda, Masakazu Hirouchi, Yasuhisa Adachi, Zhuohan Hu & Yuichi Sugiyama. (2006) INVOLVEMENT OF TRANSPORTERS IN THE HEPATIC UPTAKE AND BILIARY EXCRETION OF VALSARTAN, A SELECTIVE ANTAGONIST OF THE ANGIOTENSIN II AT1-RECEPTOR, IN HUMANS. Drug Metabolism and Disposition 34:7, pages 1247-1254.
Crossref
Crossref
J. Macek, J. Klíma & P. Ptáček. (2006) Rapid determination of valsartan in human plasma by protein precipitation and high-performance liquid chromatography. Journal of Chromatography B 832:1, pages 169-172.
Crossref
Crossref
Antona J Wagstaff. (2006) Valsartan/Hydrochlorothiazide. Drugs 66:14, pages 1881-1901.
Crossref
Crossref
G Neil Thomas, Paul Chan & Brian Tomlinson. (2006) The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension. Drugs & Aging 23:2, pages 131-155.
Crossref
Crossref
Toshiro Niwa, Shinji Honda, Kiyoharu Shirakawa, Yasushi Imamura, Sadayuki Osaki & Akira Takagi. (2006) Drug interaction of fluvoxamine, a selective serotonin reuptake inhibitor. Folia Pharmacologica Japonica 128:2, pages 93-103.
Crossref
Crossref
Motoharu SonegawaHiroaki SuzakaAkira TomiyamaTsuyoshi Tomiyama. (2006) Synthesis and Pharmacological Activity of the Metabolites of Pratosartan. Chemical and Pharmaceutical Bulletin 54:6, pages 782-787.
Crossref
Crossref
Maurizio Destro, Rossana Scabrosetti, Alessandro Vanasia & Amedeo Mugellini. (2005) Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Advances in Therapy 22:1, pages 32-43.
Crossref
Crossref
Jasper Dingemanse & Paul L. M. Van Giersbergen. (2004) Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile. British Journal of Clinical Pharmacology 57:3, pages 344-348.
Crossref
Crossref
Boris Schmidt, Helmut Drexler & Bernhard Schieffer. (2004) Therapeutic Effects of Angiotensin (AT1) Receptor Antagonists. American Journal of Cardiovascular Drugs 4:6, pages 361-368.
Crossref
Crossref
Boris Schmidt & Bernhard Schieffer. (2003) Angiotensin II AT1 Receptor Antagonists. Clinical Implications of Active Metabolites. Journal of Medicinal Chemistry 46:12, pages 2261-2270.
Crossref
Crossref
Thomas Unger & Elena Kaschina. (2003) Drug Interactions with Angiotensin Receptor Blockers: A Comparison with Other Antihypertensives. Drug Safety 26:10, pages 707-720.
Crossref
Crossref
Masaaki KIMURA, Hironobu MITANI & Yasuo ISOMURA. (2002) Preclinical and clinical profile of valsartan, a selective angiotensin II type-1 receptor blocker.. Folia Pharmacologica Japonica 120:5, pages 353-360.
Crossref
Crossref
E Cagigal, L González, R.M Alonso & R.M Jiménez. (2001) pKa determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. Journal of Pharmaceutical and Biomedical Analysis 26:3, pages 477-486.
Crossref
Crossref
W. Kirch, B. Horn & J. Schweizer. (2001) Comparison of angiotensin II receptor antagonists. European Journal of Clinical Investigation 31:8, pages 698-706.
Crossref
Crossref
Per Eystein Lønning, Jürgen Geisler, Dag Clement Johannessen, Hans-Peter Gschwind, Felix Waldmeier, Werner Schneider, Bruno Galli, Tammo Winkler, Wolfgang Blum, Hans-Peter Kriemler, William Russell Miller & Johann Werner Faigle. (2001) Pharmacokinetics and metabolism of formestane in breast cancer patients. The Journal of Steroid Biochemistry and Molecular Biology 77:1, pages 39-47.
Crossref
Crossref
Michael F. Leidig, Christian Delles, Christian Kuchenbecker, Rainer-Ainer-Max Lederle, Gottfried Weidinger & Roland E. Schmieder. (2001) Pharmacokinetics of Valsartan in Hypertensive Patients on Long-Term Haemodialysis. Clinical Drug Investigation 21:1, pages 59-66.
Crossref
Crossref
Ettore Malacco, Simona Piazza, Rachele Meroni & Anna Milanesi. (2000) Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: a randomized, open-label, crossover study. Current Therapeutic Research 61:11, pages 789-797.
Crossref
Crossref
Th. Moenius, R. Voges, P. Burtscher & Ch. Züger. (2000) Carbon-14 labelling of DIOVAN™ in its valine-moiety. Journal of Labelled Compounds and Radiopharmaceuticals 43:13, pages 1245-1252.
Crossref
Crossref
Harald Seeger, Alfred O. Mueck & Theodor H. Lippert. (2000) Effects of valsartan and 17β-estradiol on the oxidation of low-density lipoprotein in vitro. Coronary Artery Disease 11:4, pages 347-349.
Crossref
Crossref
Roberto Fogari, Annalisa Zoppi, Amedeo Mugellini, Paola Preti, Alessandra Banderali, Rosa Maria Pesce & Alessandro Vanasia. (1999) Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Current Therapeutic Research 60:4, pages 195-206.
Crossref
Crossref
Gordon T. McInnes. (1999) Clinical Advantage of Valsartan. Cardiology 91:Suppl. 1, pages 14-18.
Crossref
Crossref
Franz von Bruchhausen, Siegfried Ebel, Eberhard Hackenthal, Ulrike Holzgrabe, Margitta Albinus, Gudrun Amschler, Erwin von Angerer, C. Arras-Reiter, Andrea Bauer, Pia Bauer, Winfried Beil, Thorsten Beyrich, Katja Binder, Roswitha Böhme, Hans-Hubertus Borchert, Franz Bossle, Franz Bracher, Helmut Bräunlich, Ellen Bretschneider, Regina Brigelius-Flohé, Kerstin Brinkmann, Axel Büge, Wolfram Christ, Monika Cimbollek, Rolf Daniels, Gerd Dannhardt, Hans-Jürgen Duchstein, Kurt Eger, Petra Eichhorn, Michael Engler, Thomas Erker, Peter Felfe, Alfred Fenyves, Reinhard Fescharek, Carmen Frackenpohl, August Wilhelm Frahm, Margarete Frahm, Volker Franke, Ulrich Franken, Detlef Geffken, Uli Geis, Erika Glusa, Berthold Göber, Peter Ndive Gobina, Werner Golder, Margarete Goppelt-Strübe, Katharina Götte, Erkme Gottstein, Michael Grosam, Markus von Gruchalla, Michael Gütschow, Annette Häfner, Boris Haluszczynski, Achim Harder, Sabine Hartmann, Susanne Hartmann, Dieter Heber, Gerhard Heinemeyer, Eberhard Heller, Dietrich von Herrath, J. Hilfenhaus, Ute Hoffmann-Schollmayer, Bernhard Hofmann, Christian Holpert, Ute Hübner-Steiner, Elisabeth Inkmann, Jens Jürgens, Brigitte Kaiser, Dieter-Abbo Kalbhen, Hans Kemmler, Werner Kiefer, Christoph Klett, Stephanie Klett, Martin Klingmüller, Hans-Peter Klöcking, Gerd Kobal, Axel Kramer, Mareta Kreher, M. Krüger, Markus Kuhn, Marion Sylvia Lehner, Detlef Leopoldt, Georg Liedtke, Detlef Manns, Wolfgang Matthiessen, Andreas Maurer, Wolfgang Meindl, Klaus Menges, Paul Messinger, Frank Peter Meyer, Wolfgang Meyerhof, Manfred Moos, Rudolf Morgenstern, Klaus Müller, Walter E. Müller, Corina Nachtsheim, Tilo Netzer, Michael Neugebauer, Werner Neupert, Peter Nickel, Peter Nuhn, Bernd Nürnberg, H. Oelschläger, Joachim Oertel, Michael Oettel, Hartmut Oßwald, Robert Ott, Tilmann Ott, Thomas Otzen, Peter Pachaly, Helmut Pelzer, Karl-Uwe Petersen, Rainer Pick, Martina Pickert, Andreas Pies, Eberhard Reimann, Joachim Richter, Kai Riecke, Suzanne Ritter, Hans Rommelspacher, Ulrich Rose, Gernot Roth, Gerhard Rücker, Judith Schäfer, Joachim G. Schantl, Helmut Schlager, Hildegard Schleinitz, Max Schmauß, Helmut Schmidhammer, Gerhard Schmidt, Timo Schmidt, B. Schneeweiß, Johannes Schräder, Thomas Schulz, Gert Schulze, Peter Schwanz, Johannes Schweiger, Gisela Skopp, Gisela Skorka, Kai Smolinka, Ulrich Speck, Ralf Stahlmann, Herbert Stein, Karlheinz Stiefvater, Karl-Heinz Surborg, Ulf Sürig, Hubert Szelényi, Istvan Szelenyi, Alfred Täufel, Ruth Thieroff-Ekerdt, Reinhard Troschütz, Michael Verborg, Eugen J. Verspohl, Sabine Vogel, Franz-Josef Volk, Thomas Vorwerk, Jürgen Wallmann, Martin Wenzel, Marion Weyandt-Spangenberg, Sandra Wich, Reinhold Wintersteiger, Frauke Woltmann, Beate Wüst, G. Zilow & A. Kluge. 1999. Hagers Handbuch der Pharmazeutischen Praxis. Hagers Handbuch der Pharmazeutischen Praxis
713
726
.
Martin Pfaffendorf. (2016) Angiotensin-Converting Enzyme Inhibitors an Angiotensin II-Receptor Antagonists. Seminars in Cardiothoracic and Vascular Anesthesia 2:3, pages 222-230.
Crossref
Crossref
Nimish N. Vachharajani, Wen Chyi Shyu, Theodore J. Chando, Donald W. Everett, Douglas S. Greene & Rashmi H. Barbhaiya. (2013) Oral Bioavailability and Disposition Characteristics of Irbesartan, an Angiotensin Antagonist, in Healthy Volunteers. The Journal of Clinical Pharmacology 38:8, pages 702-707.
Crossref
Crossref
Laurence J. Brookman, Paul E. Rolan, Irving S. Benjamin, Kelvin R. Palmer, Peter J. Wyld, Peter Lloyd, Gérard Flesch, Felix Waldmeier, Antoine Sioufi & Frank Mullins. (1997) Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology & Therapeutics 62:3, pages 272-278.
Crossref
Crossref
Xueting Shao, Yue-Tong Zhao, Bing Jiang, Yanying Li, Jianguo Lin & Degao Wang. (2022) Estimating Hypertension, Diabetes, and Gout Prevalence to Evaluate Public Health by Wastewater-Based Epidemiology. SSRN Electronic Journal.
Crossref
Crossref